We are live on ! Find out more
REVB icon

Revelation Biosciences
REVB

2 hedge funds and large institutions have $3.44M invested in Revelation Biosciences in 2022 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% less ownership

Funds ownership: 0% → 0% (-0%)

71% less funds holding

Funds holding: 7 → 2 (-5)

71% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 7

89% less capital invested

Capital invested by funds: $31.7M → $3.44M (-$28.3M)

Holders
2
Holders Change
-5
Holders Change %
-71.43%
% of All Funds
0.03%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
–
Reduced
–
Closed
7
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Axa
Axa
France
+$6.38M
2
MIM
Monashee Investment Management
Massachusetts
+$2.55M

Top Sellers

Rank Fund Capital Flow
1
KIM
Karpus Investment Management
New York
-$8.58M
2
WAM
Weiss Asset Management
Massachusetts
-$4.98M
3
Hudson Bay Capital Management
Hudson Bay Capital Management
Connecticut
-$4.52M
4
WRBC
W.R. Berkley Corp
Connecticut
-$3.3M
5
SCM
Shaolin Capital Management
Florida
-$2.48M

REVB Hedge Fund Activity: Q1 2022 in Review

2 of the 6,358 institutional investors tracked by Wall St. Rank reported a position in Revelation Biosciences (REVB) for Q1 2022, worth a combined $3.44M — down 89% from $31.7M a quarter earlier.

Sellers outnumbered buyers: 7 funds closed out of REVB and 2 opened new positions — a net loss of 5 holders — while 0 trimmed existing stakes and 0 added.

The largest buyer was Axa, opening a new position worth an estimated $6.38M. The largest seller was Karpus Investment Management, exiting entirely with an estimated $8.58M sold.

  • 2 institutional investors held Revelation Biosciences (REVB) as of Q1 2022, down from 7 in Q4 2021.
  • Funds reported $3.44M of Revelation Biosciences stock for Q1 2022, down 89% quarter-over-quarter.
  • 2 funds opened new Revelation Biosciences positions in Q1 2022 and 7 closed out, a net change of -5 holders.
  • The largest Revelation Biosciences buyer in Q1 2022 was Axa, an estimated $6.38M added.
  • The largest Revelation Biosciences seller in Q1 2022 was Karpus Investment Management, an estimated $8.58M sold.

Based on aggregated 13F filings for Q1 2022.